Structure-activity relationships among di- and tetramine disulfides related to benextramine
摘要:
The synthesis and irreversible alpha-blocking activity in the rat vas deferens of a series of tetra- and diamine disulfides 2-38, structural analogues of benextramine (BHC), are described. All compounds containing a central cystamine moiety displayed an irreversible alpha-adrenergic blockade at concentrations ranging from 10(-4) to 6 X 10(-6)M. Potency was increased in cystamines N,N'-disubstituted with 6-aminohexyl groups, especially when the outer nitrogen atoms bear arylalkyl substituents or are enclosed in a ring. However, N,N,N',N'-tetrasubstituted cystamines were poor blockers. Structural specificity in the outer portion of the tetramine disulfide is low, since many types of substituents gave rise to potent alpha-blockers. Even replacement of the outer amines with nonbasic ethers or amides was observed to maintain irreversible alpha-blockade.
Structure-activity relationships among di- and tetramine disulfides related to benextramine
摘要:
The synthesis and irreversible alpha-blocking activity in the rat vas deferens of a series of tetra- and diamine disulfides 2-38, structural analogues of benextramine (BHC), are described. All compounds containing a central cystamine moiety displayed an irreversible alpha-adrenergic blockade at concentrations ranging from 10(-4) to 6 X 10(-6)M. Potency was increased in cystamines N,N'-disubstituted with 6-aminohexyl groups, especially when the outer nitrogen atoms bear arylalkyl substituents or are enclosed in a ring. However, N,N,N',N'-tetrasubstituted cystamines were poor blockers. Structural specificity in the outer portion of the tetramine disulfide is low, since many types of substituents gave rise to potent alpha-blockers. Even replacement of the outer amines with nonbasic ethers or amides was observed to maintain irreversible alpha-blockade.
[EN] SULFONYLBENZODIAZEPINONE ACETAMIDES AS BRADYKININ ANTAGONISTS<br/>[FR] SULFONYLBENZODIAZEPINONE ACETAMIDES UTILISES COMME ANTAGONISTES DE LA BRADYKININE
申请人:ELAN PHARM INC
公开号:WO2004033436A1
公开(公告)日:2004-04-22
Disclosed are compounds, of formula (I) which are bradykinin antagonists and are useful to treat diseases or relieve adverse symptoms associated with disease conditions in mammals mediated by bradykinin. Certain of the compounds exhibit increased potency and are expected to also exhibit an increased duration of action.
[EN] AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE<br/>[FR] DÉRIVÉS D'AMATOXINE ET LEURS CONJUGUÉS COMME INHIBITEURS DE L'ARN POLYMÉRASE
申请人:NOVARTIS AG
公开号:WO2016071856A1
公开(公告)日:2016-05-12
The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (I), methods of inhibiting RNA polymerase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.e Antibody Drug Conjugates), pharmaceutical compositions comprising such cyclic peptides immunoconjugates, compositions comprising such cyclic peptides immunoconjugates with a therapeutic co-agent and methods of treatment using such cyclic peptides immunoconjugates: Formula (I).
Sulfonylbenzodiazepinone acetamides as bradykinin antagonists
申请人:——
公开号:US20040138208A1
公开(公告)日:2004-07-15
Disclosed are compounds, which are bradykinin antagonists and are useful to treat diseases or relieve adverse symptoms associated with disease conditions in mammals mediated by bradykinin. Certain of the compounds exhibit increased potency and are expected to also exhibit an increased duration of action.
Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists
申请人:——
公开号:US20040147520A1
公开(公告)日:2004-07-29
Disclosed are sulfonylquinoxalone acetamide derivatives useful as bradykinin antagonists.
本发明涉及一种作为缓激肽拮抗剂有用的磺酰基喹喔啉乙酰胺衍生物。
Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
申请人:Tung S. Jay
公开号:US20050038099A1
公开(公告)日:2005-02-17
Disclosed are compounds that are bradykinin B
1
receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B
1
receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.